- Home
- LTRX vs CLLS Comparison
LTRX vs CLLS Comparison
Compare LTRX & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRX
- CLLS
- Stock Information
- Founded
- LTRX 1989
- CLLS 1999
- Country
- LTRX United States
- CLLS France
- Employees
- LTRX 348
- CLLS N/A
- Industry
- LTRX Computer Communications Equipment
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- LTRX Telecommunications
- CLLS Health Care
- Exchange
- LTRX Nasdaq
- CLLS Nasdaq
- Market Cap
- LTRX 112.9M
- CLLS 148.1M
- IPO Year
- LTRX 2000
- CLLS 2007
- Fundamental
- Price
- LTRX $2.91
- CLLS $1.53
- Analyst Decision
- LTRX Strong Buy
- CLLS Buy
- Analyst Count
- LTRX 6
- CLLS 3
- Target Price
- LTRX $5.83
- CLLS $7.00
- AVG Volume (30 Days)
- LTRX 464.6K
- CLLS 114.3K
- Earning Date
- LTRX 02-06-2025
- CLLS 11-04-2024
- Dividend Yield
- LTRX N/A
- CLLS N/A
- EPS Growth
- LTRX N/A
- CLLS N/A
- EPS
- LTRX N/A
- CLLS N/A
- Revenue
- LTRX $155,842,000.00
- CLLS $36,042,000.00
- Revenue This Year
- LTRX N/A
- CLLS $387.77
- Revenue Next Year
- LTRX $11.33
- CLLS $11.14
- P/E Ratio
- LTRX N/A
- CLLS N/A
- Revenue Growth
- LTRX 12.96
- CLLS 46.96
- 52 Week Low
- LTRX $2.49
- CLLS $1.41
- 52 Week High
- LTRX $4.55
- CLLS $3.38
- Technical
- Relative Strength Index (RSI)
- LTRX 34.15
- CLLS 45.06
- Support Level
- LTRX $2.88
- CLLS $1.51
- Resistance Level
- LTRX $4.27
- CLLS $1.62
- Average True Range (ATR)
- LTRX 0.21
- CLLS 0.09
- MACD
- LTRX -0.07
- CLLS 0.01
- Stochastic Oscillator
- LTRX 2.16
- CLLS 29.17
About LTRX Lantronix Inc.
Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.